Project Grant R01HL175360
Award Date
5/1/25
Completion Date
4/30/29
Dollars Obligated
$789K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
The University of California, San Diego has been awarded a $1,451,467 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to investigate the mechanisms governing the development of diverse cardiovascular cell types from juxta-cardiac field progenitors. The 4-year grant, effective July 1, 2024, will employ a multidisciplinary approach including experimental and computational systems biology to: 1) examine the contribution of...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $294,993 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Sensoriis Inc. located in Edmonds, WA. The project aims to develop a Zebrafish Automatic Cardiovascular Assessment System (ZACAS) to enable fast, economic, and reliable assessment of cardiac function in developing zebrafish embryos. The system will include novel housing chambers, camera...
This $1,344,373 Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) supports research to investigate cardiac regeneration in human cells and zebrafish models. The primary objectives are to: (I) assess the dynamic gene regulatory networks involved in zebrafish heart regeneration using single-cell ATAC-seq, (II) interrogate the reactivation of developmental gene programs in human cardiac organoids after injury using multiomics...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,204,160 to evaluate the AMPK-BACH1-NRF2 pathway as a potential therapeutic target for inherited dilated cardiomyopathy (DCM). The primary goal is to determine if activating this signaling pathway can restore contractile function in multiple forms of inherited DCM, including those caused by mutations in myofilament and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to identify novel transcriptional regulators of endocardial-specific gene expression and understand their role in heart development, homeostasis, and regeneration. The overall project aims to delineate the gene regulatory networks controlling endocardial specification and function. Key objectives include determining how...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $751,980 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Oregon Health & Science University (OHSU) to investigate how cardiomyocyte growth is regulated in a fetal ovine model of reduced left ventricular filling. The goal is to understand how cardiomyocytes, the heart's muscle cells, grow and respond differently in fetuses with impaired left heart inflow, similar to the condition seen in Hypoplastic Left Heart...
The National Heart, Lung, and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), awarded a $242,310 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF). This grant, effective July 1, 2024 through November 30, 2026, will support UCSF's research to adapt cell-based therapies for the treatment of pulmonary fibrosis. As a leading academic medical research institution, UCSF...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,454,955 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Beckman Research Institute of the City of Hope. The funding will support research to characterize the role of the RPS6KB1 protein as an integrative player in the pathological cardiac remodeling that occurs in hypertensive heart disease and heart failure. Key components of the research include further studying the mechanisms of RPS6KB1...
This $605,275 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to delineate the developmental mechanisms controlling left-right patterning of the interventricular septum and how perturbations lead to ventricular septal defects. The grant funds work to test hypotheses that the secreted guidance cues netrin-1 (NTN1) and slit-2 (SLIT2) regulate boundary positioning and integrity, respectively, to segregate left...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research into the Hippo-YAP signaling pathway and its role in cardiac regenerative repair. The $693,261 award, effective January 10, 2025 through December 31, 2028, aims to develop gene therapy strategies that can enhance cardiac function and promote regenerative responses following myocardial infarction. The research will...